Step 1 of 2
In this assessment of participants in the phase III open-label ISLEND-2 study, investigators used descriptive statistics and validated and de novo questionnaires to evaluate quality of life in persons with virologically suppressed HIV who switched from daily oral standard-of-care ART to once-weekly islatravir/lenacapavir.